What is ironic is that I actually have Dave Mcclure's email/number, I reached out to him personally and he didn't so much as respond. It was quite a realization of how things work in SV. This week has been very tough, and disappointing. We will continue to bootstrap using grants from the NIH until something better comes along our way.
Pharm is a terrible market to get funded in, if only because it's highly speculative, has very long lead times, and uncertain returns. Have you looked into angel funding instead of VC? For example, something like Dallas' Health Wildcatters (http://healthwildcatters.com/), which is an angel syndicate that currently has an oncology pharma company in their portfolio. Private equity might also be an option -- you'll give up control, but less so than you would in an outright buyout.
Obviously, the key questions are going to be where you are in trials, what universities you've partnered with, pretty much anything that could reduce investor risk. An 80% reduction in tumorigenesis (which kinds?) is a pretty bold claim, but definitely is an attention-getter!